Zacks Investment Research lowered shares of Corium International Inc. (NASDAQ:CORI) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
CORI has been the topic of several other reports. Needham & Company LLC reiterated a buy rating and set a $15.00 target price on shares of Corium International in a report on Monday, September 26th. FBR & Co set a $18.00 target price on shares of Corium International and gave the stock a buy rating in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Corium International currently has an average rating of Buy and a consensus price target of $11.92.
Shares of Corium International (NASDAQ:CORI) opened at 5.53 on Tuesday. Corium International has a 52 week low of $3.14 and a 52 week high of $9.93. The stock’s 50 day moving average is $5.79 and its 200-day moving average is $4.59. The company’s market cap is $123.65 million.
Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. Corium International had a negative net margin of 104.77% and a negative return on equity of 158.38%. On average, equities analysts anticipate that Corium International will post ($1.62) earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in CORI. Paloma Partners Management Co purchased a new stake in Corium International during the second quarter worth $152,000. Geode Capital Management LLC boosted its stake in Corium International by 1.6% in the first quarter. Geode Capital Management LLC now owns 76,871 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 1,187 shares in the last quarter. State Street Corp boosted its stake in Corium International by 82.4% in the first quarter. State Street Corp now owns 132,615 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 59,905 shares in the last quarter. Opaleye Management Inc. boosted its stake in Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock worth $1,390,000 after buying an additional 5,000 shares in the last quarter. Finally, RTW Investments LLC boosted its stake in Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock worth $2,960,000 after buying an additional 24,629 shares in the last quarter. Institutional investors and hedge funds own 88.15% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.